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Abstract
Background: Minocycline, a semi-synthetic tetracycline antibiotic, is an effective neuroprotective
agent in animal models of cerebral ischemia when given in high doses intraperitoneally. The aim of
this study was to determine if minocycline was effective at reducing infarct size in a Temporary
Middle Cerebral Artery Occlusion model (TMCAO) when given at lower intravenous (IV) doses
that correspond to human clinical exposure regimens.
Methods: Rats underwent 90 minutes of TMCAO. Minocycline or saline placebo was administered
IV starting at 4, 5, or 6 hours post TMCAO. Infarct volume and neurofunctional tests were carried
out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium chloride (TTC) brain staining and
Neurological Score evaluation. Pharmacokinetic studies and hemodynamic monitoring were
performed on minocycline-treated rats.
Results: Minocycline at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing infarct size
when administered at 4 hours post TMCAO. At doses of 3 mg/kg, minocycline reduced infarct size
by 42% while 10 mg/kg reduced infarct size by 56%. Minocycline at a dose of 10 mg/kg significantly
reduced infarct size at 5 hours by 40% and the 3 mg/kg dose significantly reduced infarct size by
34%. With a 6 hour time window there was a non-significant trend in infarct reduction. There was
a significant difference in neurological scores favoring minocycline in both the 3 mg/kg and 10 mg/
kg doses at 4 hours and at the 10 mg/kg dose at 5 hours. Minocycline did not significantly affect
hemodynamic and physiological variables. A 3 mg/kg IV dose of minocycline resulted in serum levels
similar to that achieved in humans after a standard 200 mg dose.
Conclusions: The neuroprotective action of minocycline at clinically suitable dosing regimens and
at a therapeutic time window of at least 4–5 hours merits consideration of phase I trials in humans
in view of developing this drug for treatment of stroke.
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Background
Minocycline is a tetracycline antibiotic with demonstrated
anti-inflammatory [1-3], glutamate antagonist [3,4], and
anti-apoptotic actions [5-8] in many models of brain
injury [2,3,9-11]. These properties, along with its superior
human safety and blood-brain-barrier penetration make
it an ideal candidate for clinical trials in stroke and other
neurological diseases [12]. In focal cerebral ischemia,
minocycline has been shown to reduce infarct size by
more than 50% when administered up to 4 hours after the
onset of ischemia in a rodent model [3,11,13]. However,
the minocycline doses used in these studies were almost
30 times the weight-based dose routinely administered to
humans for anti-infective and anti-inflammatory pur-
poses [14].
Before translation of experimental stroke results to clinical
trials in stroke patients can occur, a better understanding
of the effective intravenous doses and the therapeutic win-
dow of minocycline must be obtained. The purpose of
this investigation was to determine whether doses of
minocycline which result in serum levels compatible with
human administration, are effective in experimental cere-
bral ischemia. In addition, this study explored whether
such dosing regimens of minocycline could confer neuro-
protection at a therapeutic window of at least 4 hours after
the onset of ischemia.
Methods
All the procedures were performed according to an insti-
tutional protocol and adhered to Institutional Animal
Care and Use Committees (IACUC) guidelines.
Temporary middle cerebral artery occlusion (TMCAO) 
model
Male Sprague-Dawley rats weighing 270 to 330 gm were
used for our studies. Rats were anesthetized with gas inha-
lation composed of 30% oxygen (0.3 L/ min) and 70%
nitrous oxide (0.7 L/min) mixture. The gas was passed
through an isoflurane vaporizer set to deliver 3% to 4%
isoflurane during initial induction and 1.5% to 2% during
surgery. An incision of the skin was made on top of the
right common carotid artery region. The fascia was then
blunt dissected until the bifurcation of the external carotid
artery and internal carotidartery was isolated. A small inci-
sion was made on the external carotid artery, and a 19 to
22 mm long segment (depending on the weight of the
animals) of 3–0 monofilament Nylon suture with a round
tip was threaded into the internal carotid artery via the
external carotid artery. The suture was advanced toward
the middle cerebral artery (MCA) region to create focal
ischemia. The suture was maintained in the vessel for 90
min then removed for reperfusion. Body temperature was
maintained with a heating pad during surgery and during
recovery from anesthesia.
Intravenous (IV) administration of minocycline
A volume of 1 ml solution per 100 g body weight was
given intravenously to all animals. Three solutions used in
the study were: minocycline 1 mg/ml in saline, minocy-
cline 0.3 mg/ml in saline, and saline alone. The corre-
sponding dosages were 10 mg/kg or 3 mg/kg minocycline
hydrochloride (Sigma, USA) or saline alone respectively.
The solutions were administered and repeated slowly
through jugular vein injection (lasting for 5 min) at three
different administration protocols after TMCAO: for the 4
hour post TMCAO protocol 3 mg/kg or 10 mg/kg was
given at 4, 8, and 12 hr; for the 5 hour post-TMCAO pro-
tocol at 5, 9, and 13 hr; and for the 6 hour post TMCAO
protocol at 6, 10, and 14 hr.
Hemodynamic monitoring
Intensive monitoring of hemodynamic parameters was
measured in animals undergoing TMCAO. The arterial
blood pressure and heart rate were measured through a
right femoral artery PE50 tubing using a PowerLab/400
data acquisition system and analyzed using PowerLab
software (ADInstruments, CO, USA) according to the
manufacturer's specification.
Femoral arterial blood samples of 0.3 ml each were
directly drawn into a 1 ml syringe with a #25 gauge needle
and analyzed for pH, oxygen (pO2) and carbon dioxide
(pCO2) using a Roche OPTI CCA E-Glu Cassette (Roche
Diagnostics Corporation, IN, USA) and an OPTI Critical
Care Analyzer (AVL Scientific Corporation, Georgia,
USA). These parameters and rectal temperature (using
Homeothermic Blanket Systems, Harvard Apparatus, MA,
USA) were studied at 10 min before TMCAO, 90 min, 240
min, and 360 min after reperfusion in rats with 90 min
TMCAO and Minocycline (10 mg/kg, IV, at 4 hr after
TMCAO) or saline (3 ml, iv, at 4 hr after TMCAO)
treatments.
Pharmacokinetic studies
In 18 animals that did not undergo TMCAO, (6 animals
received either 3, 10, or 20 mg/kg of minocycline intrave-
nously), blood samples (1 mL) were drawn from the jug-
ular vein at 30 minutes, 60 minutes, 120 minutes and 180
minutes after minocycline administration for assessment
of maximum serum concentration (Cmax). After the sam-
ples were allowed to clot, serum was aspirated and frozen
at -20 degrees Celsius until assayed.
Assay procedures
Minocycline was assayed using a reverse-phase high per-
formance liquid chromatographic method based on that
developed by Orti et al[15]. Sensitivity of the method was
1 mg/L. Standard curves were linear over the range of 1 to
75 mg/L.
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Infarct size
Infarct volume was measured using 2,3,5-triphenyltetra-
zolium chloride (TTC) stained brain slices (24 hr after
TMCAO). This method provides an overall measure of cell
injury presented by depleted NADPH and hence the ina-
bility to reduce TTC to its colored form.
Neurological score
Neurological deficits were examined at 24 hr after
TMCAO just prior to sacrificing the animals using a 5-
point scale adapted and modified from Zhang et al [16].
Specifically, no neurological deficit, 0 point; right
Horner's syndrome, failure to extend left forelimb, hind-
limb, turning to left and circling to left, each scored 1
point.
Statistical analyses
Two-group, repeated measures ANOVA were used to
examine differences in seven physiologic measurements:
blood pressure, heart rate, temperature, pH, PO2, PCO2,
and glucose. Six animals were used in each of two treat-
ment groups: Minocycline or saline at 4 hours following
TMCAO. Measurements were made for each physiologic
parameter at 10 minutes before TMCAO, and 90, 240 and
360 minutes following reperfusion. In each ANOVA
model, animal nested within treatment group was consid-
ered a random effect. Fixed effects included the treatment
group and time of measurement. As well, the two-factor
interaction between treatment group and time was
included in each model.
Two-factor ANOVA was used to examine differences
between treatment groups and administration times for
the proportion infarct size and neurological score. In each
model, treatment group (3 mg/kg minocycline, 10 mg/kg
minocycline, or saline) and administration time (4, 5, or
6 hours) follow TMCAO were considered as fixed effects.
The two-factor interaction between treatment group and
administration time was also included in each model. All
statistical significance was assessed using an alpha level of
0.05. Post hoc tests comparing the 3 mg/kg or 10 mg/kg
to saline within each administration time (i.e. 6 compari-
sons) were conducted using a Bonferroni correction to the
overall alpha level.
Results
Pharmacokinetic
A linear relationship was observed between peak concen-
tration and dose over the dose range studied (r = 0.998,
Figure 1). Peak concentrations averaged 3.6, 13.0 and
28.8 mg/L with 3, 10 and 20 mg/kg doses respectively. The
serum levels of MC at a 3 mg/kg dose (3.6 mg/L) were
similar to that reported in humans after a standard 200
mg dose [14].
Physiological monitoring
The results for the repeated measures ANOVA model for
each outcome are given in Table 1. For each outcome, dif-
ferences between treatment groups within time period
and differences between time period within treatment
group were examined using the adjusted least square
means of the two-factor interaction between treatment
group and time. There were no statistically significant dif-
ferences between the minocycline or saline groups within
any time point for any of the outcome measures: blood
pressure, heart rate, temperature, pH, PO2, PCO2, or
glucose.
Infarct size
Minocycline at doses of 3 mg/kg and 10 mg/kg IV was
effective at reducing infarct size at 4 hours post TMCAO
(figure 2). At doses of 3 mg/kg, minocycline reduced inf-
arct size by 42% while 10 mg/kg reduced infarct size by
56% at 24 hours. Minocycline at a dose of 10 mg/kg sig-
nificantly reduced infarct size at 5 hours by 40% and the
3 mg/kg dose significantly reduced infarct size by 34%.
With a 6 hour time window there was a non-significant
trend in infarct reduction (figure 2).
Table 1: Adjusted least square means by treatment and time from the two-group, repeated measures ANOVA model results.
Outcome Minocycline Saline
10' 90' 240' 360' 10' 90' 240' 360'
Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE Mean SE
Blood 
Pressure
102.33 2.68 102.50 2.68 102.00 2.68 100.00 2.68 113.17 2.68 102.83 2.68 101.33 2.68 98.67 2.68
Heart Rate 335.00 14.36 364.33 14.36 342.67 14.36 368.67 14.36 340.50 14.36 332.00 14.36 322.83 14.36 326.50 14.36
Temperature 36.87 0.07 37.02 0.07 37.05 0.07 37.08 0.07 37.17 0.07 37.00 0.07 36.93 0.07 37.00 0.07
pH 7.45 0.01 7.43 0.01 7.43 0.01 7.45 0.01 7.45 0.01 7.44 0.01 7.44 0.01 7.45 0.01
P02 115.83 4.84 115.83 4.84 114.83 4.84 110.67 4.84 121.00 4.84 124.67 4.84 117.17 4.84 117.50 4.84
PC02 43.17 0.87 43.66 0.87 44.50 0.87 43.17 0.87 44.17 0.87 44.00 0.87 43.83 0.87 44.17 0.87
Glucose 176.00 8.37 186.33 8.37 202.33 8.37 178.67 8.37 186.00 8.37 220.67 8.37 209.50 8.37 200.17 8.37
There were no statistically significant differences between the Minocycline or saline groups within any time point for any of the outcome measures
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Neurological score
Examination of neurological function indicated that there
was a significant amelioration of neurological deficits in
animals that received 3 mg/kg or 10 mg/kg Iv minocycline
at 4 hours post TMCAO compared to animals that
received saline placebo. A signficant improvement in neu-
rological scores was evident in the 10 mg/kg but not the 3
mg/kg dose compared to placebo at 5 hours. No signifi-
cant differences in the neurological scores were seen at the
6 hour time windows (figure 3).
Discussion
Minocycline has been shown to be neuroprotective in a
variety of animal models of both chronic neurodegenera-
tion and acute CNS injury. Besides acute ischemic stroke,
minocycline is effective in rodent models of intracerebral
hemorrhage [17] and spinal cord injury [18]. However,
the doses used in the acute CNS injury studies have been
high (44–90 mg/kg) and it is not clear if lower doses that
have been shown to be safe in humans will have a similar
neuroprotective effect. Moreover, in all the studies pub-
lished to date, minocycline has been administered by
intraperitoneal (IP) or oral route. We have recently shown
that IP administration of minocycline in rodents leads to
delayed and erratic absorption and peritoneal irritation
[19].
While oral dosing is preferred in chronic neurological dis-
eases such as Parkinson's disease, Huntington's disease,
multiple sclerosis, and amyotrophic lateral sclerosis, the
intravenous route is preferred to rapidly achieve targeted
serum and CNS levels in acute neurological disorders such
as ischemic stroke, intracerebral hemorrhage, spinal cord
injury, and traumatic brain injury. In this study, IV mino-
Serum Levels of MinocyclineFig re 1
Serum Levels of Minocycline. A linear relationship was observed between peak concentration and dose over the dose range 
studied (r = 0.998).
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cycline at doses that likely are safe in humans (3 mg/kg
and 10 mg/kg) reduced infarct size in a TMCAO model.
The dose of 3 mg/kg resulted in serum levels similar to
those reported in humans given a corresponding dose
[14]. The standard human dose of minocycline is 200 mg,
roughly equivalent to the 3 mg/kg dose found to reduce
infarct size with a time window of 4 hours in our TMCAO
model. Doses of 400 mg of minocycline appear to be safe
in humans but there is limited safety data available on
higher doses. Moreover, there is also no safety data on
minocycline administered to patients with acute ischemic
stroke. Minocycline did not have an effect on important
physiological variables such as blood pressure, pO2,
pCO2 or glucose in our animals undergoing TMCAO.
Clinical trials of neuroprotective agents in acute stroke
have failed [20]. One of the important reasons for these
failures is administering a drug in humans beyond the
time window when it is effective in rodents. Importantly,
the therapeutic time window for both 3 mg/kg and 10 mg/
kg of minocycline was 4–5 hours. This time window
would extend a potential therapeutic benefit to many
stroke patients. Since it is relatively easy to administer,
minocycline could be administered to stroke patients in
smaller community hospitals and even by Emergency
Medical Personnel in the field. Our studies and the known
favorable safety profile of minocycline indicate that mino-
cycline may be an effective agent in acute ischemic stroke
and supports initiation of phase I trials of minocycline.
Effects of MC IV dosing on infarct size at 24 hr after 90 min TMCAOFigure 2
Effects of MC IV dosing on infarct size at 24 hr after 90 min TMCAO. The post hoc tests for the proportion infarct size 
showed that within the 4-hour administration time, the 3 mg/kg (p = 0.0001) and 10 mg/kg (p = 0.0001) minocycline groups 
had significantly lower mean proportion infarct size than the saline group. At the 5-hour administration time, the 3 mg/kg (p = 
0.0010) and 10 mg/kg (p = 0.0002) minocycline groups had significantly lower mean proportion infarct size than the saline 
group. There were no statistically significant differences in the proportion infarct size between treatment groups at the 6-hour 
administration time window * the number atop the bar figure was the animal numbers of that group.
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Conclusion
Minocycline at a dose of 3 mg/kg and 10 mg/kg IV is effec-
tive at reducing infarct size with a 5 hour therapeutic time
window after TMCAO. With a dose of 10 mg/kg the win-
dow to ameliorate neurological deficits is extended to 5
hours. Phase I trials of IV minocycline in acute ischemic
stroke should be initiated.
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